DRUG INTERACTION
Severity :
Monitor Closely
may have an increased CNS depressant effect when combined with CNS depressants
No drug interaction found for promazine and .
rivastigmine
may diminish the therapeutic effect of anti-parkinson agents
procyclidine
may diminish the therapeutic effect of anti-parkinson agents
biperiden
may diminish the therapeutic effect of anti-parkinson agents
benztropine
may diminish the therapeutic effect of anti-parkinson agents
levodopa
may diminish the therapeutic effect of anti-parkinson agents
remifentanil
may have an increased CNS depressive effect when combined with opioid agonists
codeine
may have an increased CNS depressive effect when combined with opioid agonists
morphine
may have an increased CNS depressive effect when combined with opioid agonists
rivastigmine
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
procyclidine
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
biperiden
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
benztropine
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
levodopa
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
tapentadol
may increase the CNS depressant of opioid agonists
flunitrazepam
may have an increased CNS depressant effect when combined with flunitrazepam
hydroxyzine
may have an increased CNS depressant effect when combined with flunitrazepam
suvorexant
may have an increased CNS depressive effect when combined with suvorexant
buprenorphine
may have an increased CNS depressant effect when combined with buprenorphine
chlormethiazole
may have an increased CNS depressant effect when combined with CNS depressants
daridorexant
may have an increased CNS depressant effect when combined with CNS depressants
zolpidem
may have an increased CNS depressant effect when combined with zolpidem
amantadine
may decrease the therapeutic effect of anti-Parkinson agents
dexmedetomidine
may have an increased CNS depressant effect when combined with dexmedetomidine
metolazone
may increase the QTc-prolonging effect of thiazide diuretics
quinethazone
may increase the QTc-prolonging effect of thiazide diuretics
azelastine
azelastine may enhance the CNS depressant effect of CNS Depressants
olopatadine
it increases the efficacy of CNS depressants
flunarizine
may have an increased CNS depressant effect when combined with flunarizine
azelastine
may have an increased CNS depressive effect when combined with CNS depressants
oxomemazine
may have an increased CNS depressive effect when combined with CNS depressants
thalidomide
CNS depressants increase the efficacy of thalidomide
kratom
may have an increased CNS depressant effect when combined with CNS depressants
metoclopramide
may have an increasingly adverse effect when combined with antipsychotic agents
orphenadrine
may have an increased CNS depressant effect when combined with orphenadrine
paraldehyde
may have an increased CNS depressant effect when combined with paraldehyde
bromeperidol
bromperidol: they may increase the CNS depressant effect of CNS Depressants
methamphetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
mibefradil
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
indoramin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
terazosin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
atenolol
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
famprofazone
may enhance the adverse/toxic effect of amphetamines
famprofazone
may enhance the adverse/toxic effect of amphetamines
levalbuterol
may enhance the hypotensive effect of beta-blockers
acebutolol
may enhance the hypotensive effect of beta-blockers
penbutolol
may enhance the hypotensive effect of beta-blockers
pindolol
may enhance the hypotensive effect of beta-blockers
propranolol
may enhance the hypotensive effect of beta-blockers
atropine
may reduce the therapeutic effect of anti-Parkinson drugs
rivastigmine
may reduce the therapeutic effect of anti-Parkinson drugs
mepenzolate
may reduce the therapeutic effect of anti-Parkinson drugs
atropine
may reduce the therapeutic effect of anti-Parkinson drugs
rivastigmine
may reduce the therapeutic effect of anti-Parkinson drugs
mepenzolate
may reduce the therapeutic effect of anti-Parkinson drugs
mibefradil
may have an increased hypotensive effect when combined with anti-hypertensive agents
indoramin
may have an increased hypotensive effect when combined with anti-hypertensive agents
minoxidil topical
may have an increased hypotensive effect when combined with anti-hypertensive agents
phenobarbital
they increase the toxicity of other CNS depressants
isoflurane
they increase the toxicity of other CNS depressants
promazine
they increase the toxicity of other CNS depressants
ruxolitnib topical
may have an increased myelosuppressive effect when combined with myelosuppressive agents
pemetrexed
may have an increased myelosuppressive effect when combined with myelosuppressive agents
methotrexate
may have an increased myelosuppressive effect when combined with myelosuppressive agents
streptozocin
may have an increased myelosuppressive effect when combined with myelosuppressive agents
rituximab
may have an increased myelosuppressive effect when combined with myelosuppressive agents
acebutolol
may increase the effect of beta-blockers
penbutolol
may increase the effect of beta-blockers
pindolol
may increase the effect of beta-blockers
opicapone
may reduce the therapeutic effect of antiparkinson drugs
procyclidine
may reduce the therapeutic effect of antiparkinson drugs
biperiden
may reduce the therapeutic effect of antiparkinson drugs
benztropine
may reduce the therapeutic effect of antiparkinson drugs
triptorelin
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
pemetrexed
may enhance adverse myelosuppressive effects
rituximab
may enhance the risk of myelosuppression
daunorubicin
may enhance the adverse effects such as bone marrow suppression
moxetumomab pasudotox
when both drugs are combined, there may be an increase in the risk of the myelosuppressive effect of myelosuppressive agents
blinatumomab
it may increase the bone marrow suppression effects of promazine
olaparib
they enhance the effect of myelosuppression in myelosuppressive agents
sorafenib
it increases the effect of myelosuppression in myelosuppressive agents
idarubicin
may enhance the adverse effects such as bone marrow suppression
rivastigmine
it enhance the neurotoxic (central) effect of antipsychotic Agents
physostigmine
it enhance the neurotoxic (central) effect of antipsychotic Agents
edrophonium
it enhance the neurotoxic (central) effect of antipsychotic Agents
fosinopril
it enhance the neurotoxic (central) effect of antipsychotic Agents
fosnetupitant
it enhance the neurotoxic (central) effect of antipsychotic Agents
rivastigmine
it may enhance the neurotoxic (central) effect of antipsychotic Agents
physostigmine
it may enhance the neurotoxic (central) effect of antipsychotic Agents
fosinopril
it may enhance the neurotoxic (central) effect of antipsychotic Agents
fosnetupitant
it may enhance the neurotoxic (central) effect of antipsychotic Agents
galantamine
it may enhance the neurotoxic (central) effect of antipsychotic Agents
levalbuterol
May enhance the hypotensive effect of beta-Blockers
acebutolol
May enhance the hypotensive effect of beta-Blockers
betaxolol
May enhance the hypotensive effect of beta-Blockers
bisoprolol
May enhance the hypotensive effect of beta-Blockers
carvedilol
May enhance the hypotensive effect of beta-Blockers
dexfenfluramine
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
donepezil (Rx)
may enhance the neurotoxic (central) effect of antipsychotic agents
carbaryl
may enhance the neurotoxic (central) effect of antipsychotic agents
donepezil (Rx)
may enhance the neurotoxic (central) effect of antipsychotic agents
carbaryl
may enhance the neurotoxic (central) effect of antipsychotic agents
methyclothiazide
may increase the adverse or toxic effect of anti-psychotic agents
felbamate
may increase the adverse or toxic effect of anti-psychotic agents
lacosamide
may increase the adverse or toxic effect of anti-psychotic agents
lamotrigine
may increase the adverse or toxic effect of anti-psychotic agents
methsuximide
may increase the adverse or toxic effect of anti-psychotic agents
methamphetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
rufinamide
may enhance the adverse/toxic effect of antipsychotic agents
diazepam
may enhance the adverse/toxic effect of antipsychotic agents
mephenytoin
may enhance the adverse/toxic effect of antipsychotic agents
pentobarbital
may enhance the adverse/toxic effect of antipsychotic agents
perampanel
may enhance the adverse/toxic effect of antipsychotic agents
rufinamide
may enhance the adverse/toxic effect of antipsychotic agents
brivaracetam
may enhance the adverse/toxic effect of antipsychotic agents
cannabidiol
may enhance the adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the adverse/toxic effect of antipsychotic agents
pramipexole
CNS depressants increase the effect of sedation of pramipexole
calcium carbonate
antacids reduce the systemic absorption of phenothiazine derivatives
magaldrate
antacids reduce the systemic absorption of phenothiazine derivatives
omeprazole
antacids reduce the systemic absorption of phenothiazine derivatives
tiludronic acid
antacids reduce the systemic absorption of phenothiazine derivatives
almasilate
antacids may reduce the absorption of antipsychotic agents
magaldrate
antacids may reduce the absorption of antipsychotic agents
rufinamide
may increase the risk of adverse effects of antipsychotic agents
tiagabine
may increase the risk of adverse effects of antipsychotic agents
topiramate
may increase the risk of adverse effects of antipsychotic agents
acetazolamide
may increase the risk of adverse effects of antipsychotic agents
trimethadione
may increase the risk of adverse effects of antipsychotic agents
levalbuterol
may increase the hypotensive effect of beta-blockers
acebutolol
may increase the hypotensive effect of beta-blockers
propranolol
may increase the hypotensive effect of beta-blockers
sotalol
may increase the hypotensive effect of beta-blockers
timolol
may increase the hypotensive effect of beta-blockers
clobazam
may enhance the risk of adverse/toxic effect of antipsychotic agents
clorazepic acid
may enhance the risk of adverse/toxic effect of antipsychotic agents
clonazepam
may enhance the risk of adverse/toxic effect of antipsychotic agents
diazepam
may enhance the risk of adverse/toxic effect of antipsychotic agents
rufinamide
may enhance the risk of adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the risk of adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the risk of adverse/toxic effect of antipsychotic agents
clobazam
may enhance the risk of adverse/toxic effect of antipsychotic agents
clorazepic acid
may enhance the risk of adverse/toxic effect of antipsychotic agents
iloprost
may increase the hypotensive effect of antihypertensives
mibefradil
may enhance the effect of antipsychotic agents
indoramin
may enhance the effect of antipsychotic agents
terazosin
may enhance the effect of antipsychotic agents
atenolol
may enhance the effect of antipsychotic agents
pentobarbital
may enhance the adverse effect of antipsychotic agents
perampanel
may enhance the adverse effect of antipsychotic agents
phenytoin
may enhance the adverse effect of antipsychotic agents
stiripentol
may enhance the adverse effect of antipsychotic agents
donepezil (Rx)
may enhance the neurotoxic effect of antipsychotic agents
carbaryl
may enhance the neurotoxic effect of antipsychotic agents
rivastigmine
may enhance the neurotoxic effect of antipsychotic agents
cannabidiol
may enhance the adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the adverse/toxic effect of antipsychotic agents
clonazepam
may enhance the adverse/toxic effect of antipsychotic agents
diazepam
may enhance the adverse/toxic effect of antipsychotic agents
mephenytoin
may enhance the adverse/toxic effect of antipsychotic agents
rivastigmine
may diminish the therapeutic effect of antipsychotic agents
procyclidine
may diminish the therapeutic effect of antipsychotic agents
biperiden
may diminish the therapeutic effect of antipsychotic agents
benztropine
may diminish the therapeutic effect of antipsychotic agents
levodopa
may diminish the therapeutic effect of antipsychotic agents
rivastigmine
may diminish the therapeutic effect of antipsychotic agents
procyclidine
may diminish the therapeutic effect of antipsychotic agents
biperiden
may diminish the therapeutic effect of antipsychotic agents
benztropine
may diminish the therapeutic effect of antipsychotic agents
levodopa
may diminish the therapeutic effect of antipsychotic agents
may have an increased CNS depressant effect when combined with CNS depressants
lisuride
may have an increased CNS depressive effect of CNS depressants
magnesium sulfate
may have an increased CNS depressive effect when combined with CNS depressants
phenobarbital
they increase the toxicity of other CNS depressants
isoflurane
they increase the toxicity of other CNS depressants
promazine
they increase the toxicity of other CNS depressants
rufinamide
it increases the toxicity of CNS depressants
droperidol
it increases the effect of CNS depressants
mibefradil
may have an increased hypotensive effect when combined with antipsychotic agents
indoramin
may have an increased hypotensive effect when combined with antipsychotic agents
minoxidil topical
may have an increased hypotensive effect when combined with antipsychotic agents
nabilone
may have an increased CNS depressant effect when combined with cannabinoid-containing products
cannabidiol
may have an increased CNS depressant effect when combined with cannabinoid-containing products
difelikefalin
may have an increased CNS depressant effect when combined with CNS depressants
doxylamine
may have an increased CNS depressant effect when combined with CNS depressants
esketamine
may have an increased CNS depressant effect when combined with CNS depressants
ixabepilone
may have an increased CNS depressant effect when combined with CNS depressants
carisoprodol
may increase the toxic effect of CNS depressants
neostigmine
may increase the effect of antipsychotic agents
meprobamate
may increase the toxic effect of CNS depressants
carbaryl
may increase the neurotoxic effect
pindolol
may enhance the hypotensive effect
donepezil (Rx)
may have an increased neurotoxic effect when combined with antipsychotic agents
prabotulinumtoxinA
may have an increased neurotoxic effect when combined with antipsychotic agents
brexanolone
may have an increased CNS depressant effect when combined with brexanolone
deutetrabenazine
may have an increasingly adverse effect when combined with antipsychotic agents
dexmethylphenidate
may have an increasingly adverse effect when combined with dexmethylphenidate
sevoflurane
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
metoclopramide
metoclopramide: they may increase the CNS depressant effect of CNS Depressants
minocycline
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
aripiprazole
may increase the toxic effect of CNS Depressants
zonisamide
may increase the risk of adverse effect
ezogabine
may increase the risk of adverse effect
mexiletine
may increase the risk of adverse effect
zolp
CNS depressants increase the effect of zolpidem